Bhavani Nagendra Papudesi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bhavani Nagendra Papudesi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anil Bachu
Baptist Health—University of Arkansas for Medical Sciences Psychiatry Residency Program, North Little Rock, AR 72117, USA
1 shared publication - Garima Yadav
Department of Psychiatry, Texas Tech University, Permian Basin, Odessa, TX 79762, USA
1 shared publication - Kristina Kennedy
Baptist Health—University of Arkansas for Medical Sciences Psychiatry Residency Program, North Little Rock, AR 72117, USA
1 shared publication - Nagy A. Youssef
Department of Psychiatry and Behavioral Health, The Ohio State University College of Medicine, Columbus, OH 43210, USA
1 shared publication - Padma Kotapati
Baptist Health—University of Arkansas for Medical Sciences Psychiatry Residency Program, North Little Rock, AR 72117, USA
1 shared publication - Sahar Ashraf
Department of Psychiatry, JPS Health Network, Fort Worth, Texas
1 shared publication
Latest Publications
- Open Access
- 7 November 2023
- Published by MDPI AG in Psychoactives
- Vol. 2 (4) , 337-345
Use of Methylphenidate for Hypoactive Delirium: A Comprehensive Systematic Review
Background: Delirium is a complex neuropsychiatric syndrome common in all medical settings. An acute change in cognition characterizes a disturbance of consciousness, usually resulting from an underlying medical condition or withdrawal from medications or drugs. Three different subtypes of delirium have been identified based on the motor symptoms exhibited by the patient: hyperactive, hypoactive, and mixed. This study aims to review the use of methylphenidate for treating hypoactive delirium. Methods: The review was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We performed a literature search of PubMed, MEDLINE, Cochrane, and clinical trial registries from 1990 to 15 March 2023. Results: A total of 115 articles were identified. After removing duplicates, 68 abstracts were reviewed by all the authors. Then, 13 full-text articles were assessed for eligibility. Three articles were deemed eligible for the systematic review. These included one prospective clinical study, one case series, and one case report. The total number of participants was 17, with multiple comorbidities. Most studies reported using methylphenidate for hypoactive delirium in terminally ill patients. All reviewed studies reported symptomatic benefits in individuals with hypoactive delirium. Conclusions: Methylphenidate may be beneficial in treating hypoactive delirium in terminally ill patients. Clinical trials are needed to assess the safety and efficacy of methylphenidate in Hypoactive delirium.
- 7 November 2023
- Published by MDPI AG in Psychoactives
- Vol. 2 (4) , 337-345
Open AccessUse of Methylphenidate for Hypoactive Delirium: A Comprehensive Systematic Review
Background: Delirium is a complex neuropsychiatric syndrome common in all medical settings. An acute change in cognition characterizes a disturbance of consciousness, usually resulting from an underlying medical condition or withdrawal from medications or drugs. Three different subtypes of delirium have been identified based on the motor symptoms exhibited by the patient: hyperactive, hypoactive, and mixed. This study aims to review the use of methylphenidate for treating hypoactive delirium. Methods: The review was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We performed a literature search of PubMed, MEDLINE, Cochrane, and clinical trial registries from 1990 to 15 March 2023. Results: A total of 115 articles were identified. After removing duplicates, 68 abstracts were reviewed by all the authors. Then, 13 full-text articles were assessed for eligibility. Three articles were deemed eligible for the systematic review. These included one prospective clinical study, one case series, and one case report. The total number of participants was 17, with multiple comorbidities. Most studies reported using methylphenidate for hypoactive delirium in terminally ill patients. All reviewed studies reported symptomatic benefits in individuals with hypoactive delirium. Conclusions: Methylphenidate may be beneficial in treating hypoactive delirium in terminally ill patients. Clinical trials are needed to assess the safety and efficacy of methylphenidate in Hypoactive delirium.